Sarcopenia may predict recurrence in patients with head and neck cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Malnutrition in head and neck cancer (HNC) patients is linked to low skeletal muscle index (SMI). Low SMI, indicating sarcopenia, is associated with significantly higher cancer recurrence rates.
Area Of Science
- Oncology
- Radiology
- Nutrition Science
Background
- Malnutrition is a significant complication in head and neck cancer (HNC) patients, often manifesting as reduced skeletal muscle mass.
- This muscle loss, known as sarcopenia, negatively impacts patient survival and treatment outcomes.
Purpose Of The Study
- To investigate the prognostic value of sarcopenia, defined by skeletal muscle index (SMI), on survival in patients diagnosed with HNC.
- To establish the clinical relevance of low SMI at the third cervical vertebra in HNC patients.
Main Methods
- Retrospective analysis of 112 HNC patients treated at a single tertiary care center.
- Skeletal muscle index (SMI) was calculated from pre-treatment imaging at the 3rd cervical vertebra.
- Sarcopenia was defined using specific SMI thresholds for males and females, considering body mass index.
Main Results
- 61.6% of HNC patients exhibited low SMI (sarcopenia).
- Patients with low SMI had a significantly higher recurrence rate (26% vs. 2%, p=0.02).
- While not statistically significant, overall survival was lower in patients with low SMI (72.5% vs. 81%).
Conclusions
- Low skeletal muscle index (SMI) at the third cervical vertebra is a clinically relevant indicator in head and neck cancer.
- Sarcopenia, identified by low SMI, is strongly associated with increased cancer recurrence rates in HNC patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
